EUVIMEDEUVIMED entdecken
Open Access

Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Daniel J George, Alicia K Morgans, Niculae Constantinovici, Nasreen Khan, Javeed Khan, Guifang Chen, Vlasta Hlebec, Neal D Shore

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.29783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Daniel J George und 7 weiteren Autor:innen. Beteiligte Einrichtung: Duke University Cancer Institute, Durham, North Carolina. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Phenylthiohydantoin, Benzamides. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Novel androgen receptor inhibitors (ARIs; darolutamide, enzalutamide, and apalutamide) are standard-of-care treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC). However, there are sparse data comparing their clinical use and tolerability.

Objective

To compare clinical use and outcomes for darolutamide, enzalutamide, and apalutamide in patients with nmCRPC. Design, Setting, and Participants This retrospective cohort study reviewed electronic medical records from the Precision Point Specialty network of US urology practices. Eligible patients had nmCRPC and no prior novel hormonal therapy and initiated novel ARI treatment between August 1, 2019, and March 31, 2022. Data were analyzed from February 1, 2019, to December 31, 2022. Exposures Patients were prescribed darolutamide, enzalutamide, or apalutamide as their first novel ARI for nmCRPC. Main Outcomes and Measures The main outcome was a composite of 2 end points, treatment discontinuation and progression to metastatic CRPC (mCRPC), whichever occurred first. Both end points were also assessed separately.

Results

All 870 patients meeting eligibility criteria were included (362 receiving darolutamide [41.6%]; 382, enzalutamide [43.9%]; 126, apalutamide [14.5%]); mean (SD) age was 78.8 (8.7) years. Self-reported race was Black or African American in 187 patients (21.5%), White in 585 (67.2%), and other or unknown in 98 (11.3%). The darolutamide cohort had lower proportions of patients with a composite end point event (134 [37.0%] vs 201 [52.6%] for enzalutamide and 66 [52.4%] for apalutamide), discontinuation (110 [30.4%] for darolutamide vs 156 [40.8%] for enzalutamide and 58 [46.0%] for apalutamide), and progression to mCRPC (64 [17.7%] for darolutamide vs 108 [28.3%] for enzalutamide and 35 [27.8%] for apalutamide) during the study period. After adjusting for baseline covariates, patients receiving darolutamide had a lower risk of a composite end point event compared with enzalutamide (risk reduction, 33.8%; hazard ratio [HR], 0.66 [95% CI, 0.53-0.84]) and apalutamide (risk reduction, 35.1%; HR, 0.65 [95% CI, 0.48-0.88]). Similarly, patients receiving darolutamide had a lower risk of discontinuation compared with enzalutamide (risk reduction, 27.4%; HR, 0.73 [95% CI, 0.56-0.94]) and apalutamide (risk reduction, 39.1%; HR, 0.61 [95% CI, 0.44-0.85]) and a lower risk of progression to mCRPC compared with enzalutamide (risk reduction, 40.6%; HR, 0.59 [95% CI, 0.43-0.82]) and apalutamide (risk reduction, 35.3%; HR, 0.65 [95% CI, 0.42-0.99]). There was no difference between enzalutamide and apalutamide treatment across outcomes. Conclusions and Relevance In this large cohort study of patients with nmCRPC treated with novel ARIs, results suggest better tolerability for darolutamide compared with enzalutamide and apalutamide, which may be associated with a clinical effectiveness advantage. Comparative clinical studies are needed to guide treatment decisions in the absence of head-to-head clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsPhenylthiohydantoinBenzamidesNitrilesThiohydantoinsHumansMaleAgedRetrospective StudiesPyrazolesAged, 80 and overMiddle Aged

Substanzen

enzalutamideAndrogen Receptor AntagonistsPhenylthiohydantoinBenzamidesNitrilesdarolutamideThiohydantoinsapalutamidePyrazoles

Autor:innen und Institutionen

  • Duke University Cancer Institute, Durham, North Carolina.
  • Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Bayer Consumer Care AG, Basel, Switzerland.
  • Bayer HealthCare Pharmaceuticals, Whippany, New Jersey.
  • Bayer plc, Reading, United Kingdom.
  • Carolina Urologic Research Center, Myrtle Beach, South Carolina.

Zitieren

APA

George, D. J., Morgans, A. K., Constantinovici, N., Khan, N., Khan, J., Chen, G., Hlebec, V., & Shore, N. D. (2024). Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.29783

Vancouver

George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, et al. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.29783

BibTeX
@article{George2024,
  author = {George, Daniel J and Morgans, Alicia K and Constantinovici, Niculae and Khan, Nasreen and Khan, Javeed and Chen, Guifang and Hlebec, Vlasta and Shore, Neal D},
  title = {Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.29783}
}
Kostenlos starten →